Concepedia

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma

Brian I. Rini, Bohuslav Melichar, Mayer Fishman, Mototsugu Oya, Yazdi K. Pithavala, Y. Chen, A. Bair, Viktor Grünwald

Annals of Oncology · 2015 · 75 citations · 10 references

DOIFull text

Open access

Concepts

References

10

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Sandrine Faivre, Catherine Delbaldo, Karina Vera et al. · Journal of Clinical Oncology · 2005 · 1.2K citations · Full text

, , +17

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini et al. · Clinical Cancer Research · 2008 · 628 citations

, , +17

Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results

Hope S. Rugo, Roy S. Herbst, Glenn Liu et al. · Journal of Clinical Oncology · 2005 · 485 citations · Full text

, , +17

Phase I Trial of Pazopanib in Patients with Advanced Cancer

Herbert I. Hurwitz, Afshin Dowlati, Shermini Saini et al. · Clinical Cancer Research · 2009 · 413 citations · Full text

, , +14

Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

Michael L. Maitland, George L. Bakris, Henry R. Black et al. · JNCI Journal of the National Cancer Institute · 2010 · 407 citations · Full text

, , +17